Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: 960404-59-5
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Based on two acute toxicity studies in rat (oral and dermal), 28 day oral study in rats and oral (daily) Study of Fertility and Early Embryonic Development (rat). Also consideration of the substances water solubility, partition coefficient , molecular mass and particle size.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 100
Additional information
oral: evidence presented by the acute oral toxicity study indicates that the substance is absorbed following administration in arachis oil with systemic effects noted at the high dose; increased liver enzymes, increase in blood cholesterol, increased liver weight with associated microscopic hepatocyte hypertrophy. Additionally, no toxicologically significant effects were observed on reproductive or developmental parameters in the exposed animals.
The water solubility, partition coefficient and molecular mass all indicate that this substance will be bioavailable via the oral route.
Inhalation: The particle size distribution indicates that there is limited potential for exposure by this route.
Dermal absorption: Results from in vivo irritation and dermal toxicity studies, in addition to the physical parameters of molecular weight and log Pow, indicate that the substance can penetrate the stratum corneum and is systemically available from dermal exposure.
Metabolism:
No specific metabolism studies have been undertaken however there is limited evidence from the 28 day study to indicate that the substance is undergoing hepatic metabolism (increase in ALAT and liver weight, incidence of microscopic hepatocyte hypertrophy).
Distribution: No specific distribution studies have been conducted, however limited evidence from the 28 Day study (changes in haematological parameters (Hb, RDW, counts of neutrophils, lymphocytes, reticulocytes), clinical biochemical parameters (prot, chol, Ca, Cl, ALAT), urinalysis (volume, glu, Na, pH), organ weight of liver, prostate gland, uterus, thymus (f), and microscopic findings (hypertrophy in cells of thyroid, trachea, liver, adrenals, haematopoiesis-spleen). ) indicates that the substance is distributed throughout the body.
Excretion: No specific excretion studies have been conducted however the physical characteristics (MW, water solubility and partition coefficient), changes to the clinical chemistry (Ca, Cl) and urinanalysis profile (volume, Na, pH) of treated animals would suggest that the substance or its metabolites interact with, or are excreted by the kidneys.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
